Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2024-11-05 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1382342
Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan
{"title":"Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.","authors":"Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan","doi":"10.3389/fphar.2024.1382342","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.</p><p><strong>Methods: </strong>A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.</p><p><strong>Results: </strong>The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.</p><p><strong>Conclusion: </strong>Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1382342"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573544/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1382342","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.

Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.

Results: The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.

Conclusion: Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估尼妥珠单抗加吉西他滨-顺铂治疗 aUC 在中国的成本效益。
目的:从中国支付方的角度评估尼伐单抗联合吉西他滨-顺铂治疗晚期尿路上皮癌(aUC)的成本效益:采用马尔可夫模型评估经济结果,以质量调整生命年(QALYs)估算健康结果。进行了单向和概率敏感性分析,以评估不确定性对结果的影响:基础病例分析显示,Nivolumab联合吉西他滨-顺铂治疗可获得0.59个质量调整生命年,额外成本为78,780.61美元,增量成本效益比(ICER)为133,526.46美元/质量调整生命年。单向敏感性分析强调了Nivolumab的成本是关键因素,而概率敏感性分析表明,在aUC治疗中,Nivolumab联合吉西他滨-顺铂的成本效益几率为0%:结论:Nivolumab 联合吉西他滨-顺铂治疗 aUC 不具成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
Evaluating in vivo data for drug metabolism and transport: lessons from Kirchhoff's Laws. Exploring the mechanism of sesamin for the treatment of PM2.5-induced cardiomyocyte damage based on transcriptomics, network pharmacology and experimental verification. Exploring the therapeutic mechanisms of heart failure with Chinese herbal medicine: a focus on miRNA-mediated regulation. Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China. Knowledge domain and trends in treatment-resistant schizophrenia (TRS) research based on CiteSpace bibliometrics analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1